
News|Articles|February 20, 2025
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
Author(s)Giuliana Grossi
While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Advertisement
Advertisement
Health care access and equity have recently faced mounting challenges across the US shaped by legislative policies, social determinants, and evolving treatment landscapes—a trend that appears set to accelerate in 2025. Abortion bans in the wake of the Dobbs v Jackson Supreme Court decision in 2022 and the preceding Texas Senate Bill 8 (SB8) in 2021 have introduced legal and ethical dilemmas, prompting a nationwide conversation including various perspectives among physicians, authors, and lawmakers.
Related to this article

HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.

Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.

As National Family Caregivers Month begins, AJMC presents coverage from PCOC's first-ever panel on caregiving, where participants discuss demands on family members who are the “eyes and ears” when patients receive CAR T, bispecific, or transplant treatments.

AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.

Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.

October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.

PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
Advertisement
Advertisement

